3rd Quarter - Report

APCO WORLDWIDE LLC for HIKMA PHARMACEUTICALS USA INC.

Firm
Client
Income
$70,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Trade policies impacting domestic generic pharmaceutical manufacturing

Foreign entity interest: Hikma Pharmaceuticals PLC, identified in the LD-1, has an indirect interest in U.S. policy relating to health and pharmaceutical products.

LobbyistCovered position, as disclosed
MIKASA MODI —
ALLISON PARKER-LAGOO Assistant to the Chief of Staff, Sen. Hagan
DAN SCANDLING Chief of Staff & Press Secretary, Rep. Bateman

Contacted: SENATE; Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES

Health Issues HCR

Health and pharmaceutical policies and domestic pharmaceutical manufacturing supply chain issues and drug shortage issues

Foreign entity interest: Hikma Pharmaceuticals PLC, identified in the LD-1, has an indirect interest in U.S. policy relating to health and pharmaceutical products.

LobbyistCovered position, as disclosed
MIKASA MODI —
ALLISON PARKER-LAGOO Assistant to the Chief of Staff, Sen. Hagan
DAN SCANDLING Chief of Staff & Press Secretary, Rep. Bateman

Contacted: Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.